Bio


I am a general surgery resident physician at Stanford University. I obtained my MD with Honors at the University of Chicago in 2022. My research, which is funded through an F32 National Research Service Award from the National Institutes of Health, focuses on improving organ allocation policies and promoting equity in access to transplantation. In particular, I study how organ allocation systems prioritize patients for transplantation, how transplant centers respond to changes in national allocation policies, and how clinical data can be used to develop more accurate and equitable measures of medical urgency. My long-term goal is to become an academic transplant surgeon whose research informs evidence-based transplant policy and improves outcomes for patients with end-stage organ failure. My work has appeared in journals including JAMA, Journal of the American College of Cardiology, Circulation: Heart Failure, Journal of Heart and Lung Transplantation, and American Journal of Transplantation.

Honors & Awards


  • Medical Student Research Fellowship, The National Kidney Foundation of Illinois (2019)

All Publications


  • Unintended Shifts in High-Priority Adult Heart Transplant Listings after the OPTN's September 2025 Policy Change. The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation Ramos, C., Horwitz, A., Singer, R., White, M., Narang, N., Khush, K. K., Parker, W. F., Ahn, D. J. 2026

    Abstract

    The Organ Procurement and Transplantation Network amended Status 2 heart allocation criteria in September 2025, requiring documented failure of high-dose inotropes before candidates could qualify via intra-aortic balloon pump (IABP) or percutaneous endovascular ventricular assist device (PEVAD) support. Using OPTN data, we compared seasonally matched pre-policy (September 2024-June 2025, n=4,206) and post-policy (September 2025-June 2026, n=4,231) adult candidates. While standard Status 3 high-dose inotrope listings increased 2.0% to 4.1% and standard Status 2 IABP/PEVAD listings decreased 18.2% to 11.0%, Status 1 listings and Status 2 exceptions increased 7.7% to 10.6% and 17.5% to 21.5%, respectively (all p<0.001). Consequently, combined initial Status 1/2 listings were unchanged (44.5% vs 44.0%, p=0.71). Furthermore, overall transplant volume remained similar, but status at transplant shifted from standard Status 2 toward Status 2 exceptions and Status 1. Tightening standard Status 2 eligibility was associated with redistribution across high-priority pathways rather than reduced high-priority listings.

    View details for DOI 10.1016/j.healun.2026.10.012

    View details for PubMedID 42892347

  • Development and Validation of an Adult Medical Urgency Score for US Donor Heart Allocation. JAMA Lyden, G. R., White, M., Ahn, D. J., Menteer, J., Daly, R. C., Narang, N., Khush, K. K., Jasseron, C., Dorent, R., Masotti, M., Wood, N. L., Colvin, M. M., Gentry, S. E., Parker, W. F. 2026

    Abstract

    One in 5 heart transplant candidates in the US die or are delisted without transplant. Donor hearts are currently allocated by a 6-status therapy-based system criticized for limited risk stratification and susceptibility to gaming.To develop a new heart allocation policy based on an objective medical urgency score that ranks candidates based on the interaction between physiology and mechanical circulatory support.Registry-based observational study using data from the US organ transplant system. All adult (aged ≥18 years) heart transplant candidates from January 2019 to August 2025 were included, split into training (2019-2023), validation (2023-2024), and test (2024-2025) datasets.A marginal structural model of 6-week mortality without transplant was estimated (the US Candidate Risk Score [US-CRS]). Eight models were compared in held-out data by weighted time-dependent area under the curve (AUC) and calibration by status. Finally, US-CRS was converted into an allocation policy and a match-run simulation of waitlist reordering was performed compared with the current 6-status system.Adult heart transplant candidates were partitioned into consecutive training (n = 21 859), validation (n = 7897), and test (n = 8256) datasets (mean [SD] age, 53 [13] years; 74% male). The chosen US-CRS model included 5 laboratory values and 4 therapeutic devices (durable left ventricular assist device, intra-aortic balloon pump, microaxial flow pump, and advanced mechanical circulatory support). In test-set cross-sections of candidates actively waiting on the same calendar date, US-CRS had similar or significantly higher time-dependent AUC than the current 6-status system (mean AUC, 0.807 vs 0.693, respectively) and acceptable calibration by status, especially for candidates who received their status by exception. In match-run analysis (n = 45 530 donor hearts), a US-CRS-based system led to 67% of transplant recipients moving down in rank order and increased observed 6-week transplant-censored mortality for the first candidate on the match run from 11.2% (95% CI, 10.1%-12.5%) under the current system to 15.7% (95% CI, 13.9%-17.6%) under the US-CRS-based system.In this registry-based study of US heart transplant candidates, a US-CRS-based allocation system prioritized sicker candidates with higher mortality without transplant compared with the current medical urgency statuses.

    View details for DOI 10.1001/jama.2026.17403

    View details for PubMedID 42862588

  • In policy and in practice: expedited placement and allocation out of sequence in liver transplantation. American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons Attia, A., Nakayama, T., Ahn, D. J., York, T., Wehrle, C. J., Cheng, X. S., Charu, V., Kwong, A. J., Stutchfield, B. M., Segev, D., Gentry, S., Melcher, M., Sasaki, K. 2026

    Abstract

    United States liver transplant policy debate has conflated two distinct mechanisms: Expedited Placement (OPTN Policy 9.10), a formal route for late turndowns when in-sequence offering risks non-utilization, and allocation out-of-sequence (AOOS), informal organ procurement organization (OPO) outreach beyond the match-run. Linking Standard Transplant Analysis and Research files to the Potential Transplant Recipient database (March 2021-December 2025), we classified 61,626 match-runs (41,638 transplanted) by pathway: in-sequence <50 offers (n=32,165), in-sequence ≥50 (n=3,450), AOOS (n=5,486), and Expedited Placement (n=537). AOOS rose 132% while Expedited Placement grew 6% and was absent in 12 of 55 OPOs. Before acceptance, a median 10 centers were contacted per AOOS graft versus 6 in-sequence, and AOOS refusals far more often covered entire waitlists (median 28 patients declined per donor versus 2). Most in-sequence acceptances occurred before donor cross-clamp (median 17.0 hours prior), whereas AOOS and Expedited Placement acceptances occurred after (0.15 and 2.42 hours). AOOS transplants occurred more frequently at centers with higher in-sequence acceptance of hard-to-place organs (Spearman 0.866), with comparable survival. These patterns are consistent with AOOS occurring after in-sequence placement has stalled, rather than as early bypass of in-sequence candidates; the circumstance Expedited Placement was designed for.

    View details for DOI 10.1016/j.ajt.2026.09.022

    View details for PubMedID 42763043

  • Under-Capture of Candidates Supported by Temporary Mechanical Circulatory Support in the OPTN STAR Registry. JACC. Advances Ahn, D. J., Attia, A., Nakayama, T., Parker, W. F., Khush, K. K. 2026; 5 (10 Pt 2): 103213

    View details for DOI 10.1016/j.jacadv.2026.103213

    View details for PubMedID 42721605

  • Does reperfusion time affect chances of HCC recurrence after liver transplantation? HPB : the official journal of the International Hepato Pancreato Biliary Association Gangaram, P., Attia, A. M., Ahn, D., Nakayama, T., Sasaki, K. 2026

    View details for DOI 10.1016/j.hpb.2026.08.2004

    View details for PubMedID 42767850

  • Beyond Categorical Tiers: Improving Measurement of Medical Urgency as the Foundation for Heart Allocation Reform. Journal of cardiac failure Ahn, D. J., Eap, D. K., Parker, W. F. 2026; 32 (9): 1584-1593

    Abstract

    The United States heart allocation system prioritizes transplant candidates using therapy-based categorical urgency tiers that measure treatment decisions rather than biological risk. This miscalibration is associated with observable downstream issues: status exception rates exceeding 40% of adult listings, systematic escalation of temporary mechanical circulatory support in hemodynamically stable candidates, missed opportunities for myocardial recovery, and structural inequities in access. This review argues that meaningful reform requires a sequenced agenda: developing validated continuous urgency scores grounded in objective biological variables for both adult and pediatric candidates, reforming the exception process through standardized prospectively applied criteria, and building a new allocation policy using accurate inputs.

    View details for DOI 10.1016/j.cardfail.2026.06.027

    View details for PubMedID 42710972

  • The Benefit of Sequential Normothermic Regional Perfusion and Hypothermic Machine Perfusion in Kidney Transplantation From Donation After Circulatory Death Donors. Clinical transplantation Nakayama, T., Fu, S. J., Attia, A. M., Ahn, D. J., Pham, T. A., Melcher, M. L., Bozhilov, K. K., Sasaki, K. 2026; 40 (8): e70641

    Abstract

    Normothermic regional perfusion (NRP) is associated with improved posttransplant outcomes in donation after circulatory death (DCD) kidney transplantation. It remains unknown whether hypothermic machine perfusion (HMP) offers additional benefits over static cold storage (SCS) during transport.All adult kidney-only transplantations from DCD donors procured by NRP in the OPTN data (10/1/2020-6/30/2025) were identified. Primary exposure was preservation method during transport: NRP combined with HMP (NRP+HMP) or SCS (NRP+SCS). One-to-two propensity score matching (PSM) was performed on fifteen donor and recipient factors. Primary outcomes included delayed graft function (DGF), posttransplant length of stay (LOS), and estimated glomerular filtration rate (eGFR) at 6 months posttransplant. Secondary outcomes were one-year graft and patient survival.Among 4792 NRP cases, HMP was utilized in 85.1%, with its use increasing over time. After 1:2 PSM (685 NRP+SCS matched to 1262 NRP+HMP), NRP+HMP was associated with significantly lower DGF (23.3% vs. 30.5%, p < 0.01). Median LOS (4.0 days in both groups, p = 0.07), 6-month eGFR (58.5 vs. 60.1 mL/min/1.73m2, p = 0.46), one-year graft survival, and one-year patient survival were not significantly different. The association between HMP and lower DGF was observed across KDPI strata, heart recovery status, and cold ischemia time categories, with no significant interactions detected.The adoption of HMP after NRP has increased substantially in the United States and was associated with reduced DGF, but no difference was observed for LOS, 6-month eGFR, graft survival, and patient survival. These findings support the routine use of HMP after NRP.

    View details for DOI 10.1111/ctr.70641

    View details for PubMedID 42599744

    View details for PubMedCentralID PMC13475596

  • Undercapture of HeartMate 3-Supported Pediatric Candidates in the OPTN STAR Registry. The Annals of thoracic surgery Ahn, D. J., Attia, A., Nakayama, T., Parker, W. F., Khush, K. K. 2026

    View details for DOI 10.1016/j.athoracsur.2026.06.066

    View details for PubMedID 42468869

  • Potential Impact of the OPTN Status Escalation Policy for Adult Heart Transplant Candidates With Durable LVADs. Circulation. Heart failure Ahn, D. J., Attia, A., Nakayama, T., Narang, N., Khush, K. K., Parker, W., Sasaki, K. 2026: e013854

    Abstract

    The 2018 heart allocation policy change substantially lowered the priority of candidates supported with durable left ventricular assist devices (LVADs) for heart transplantation. To provide stable candidates supported by durable LVADs with a quicker path to transplantation before they suffer complications, the Organ Procurement and Transplantation Network (OPTN) approved a policy stipulating that stable patients supported by durable LVADs for 6 and 8 years will obtain statuses 3 and 2, respectively.Using OPTN data, we identified all adult heart transplant candidates with a durable LVAD implanted between October 18, 2018 and May 31, 2025. We estimated the cumulative incidence of LVAD-related complications, treating transplantation and waitlist removal before experiencing complications as competing events. Furthermore, we assessed how the OPTN policy change would impact the status distribution of the waitlist.In our study cohort, 4967 adult patients who were listed for heart transplant received a durable LVAD. Transplant centers submitted 2879 justifications for status upgrades due to LVAD-related complications for 1812 (36.5%) patients. At 6 years after durable LVAD implantation, the cumulative incidence of complications and status upgrades was 42.1% (95% CI, 40.5%-43.8%), and that of transplantation was 36.0% (95% CI, 34.6%-37.6%). Of the 3779 patients who were not censored administratively, only 47 (1.2%) remained on the waitlist by 6 years after durable LVAD implantation. Had the 6- to 8-year OPTN policy change been implemented on June 1, 2025, only 4.7% of the waitlist would have changed statuses instantaneously.Almost all listed candidates with durable LVADs either experience a complication, status upgrade or are removed from the waitlist within 6 years of obtaining a durable LVAD. The upcoming OPTN policy is unlikely to prevent device complications before granting status upgrades and will likely impact a small percentage of candidates with durable LVADs.

    View details for DOI 10.1161/CIRCHEARTFAILURE.125.013854

    View details for PubMedID 42335275

    View details for PubMedCentralID PMC13293278

  • High Rate of Transplantation Before Review of Status Exception Requests Among Adult Heart Transplant Candidates. Circulation. Heart failure Ahn, D. J., Nakayama, T., Attia, A., White, M., Eap, D., Narang, N., Khush, K. K., Parker, W. F., Sasaki, K. 2026: e013994

    Abstract

    In the US heart allocation system, when transplant centers submit applications for status exceptions to increase waitlist priority, patients obtain the requested status upgrades immediately while their applications are sent to the regional review boards (RRBs) and reviewed retrospectively. How often transplants occur during this period is unknown.Using the Scientific Registry of Transplant Recipients, we identified all adult heart transplant candidates listed between October 18, 2018, and May 31, 2025, with submitted applications for status exceptions. We assessed (1) the time elapsed between submission of exception applications and their receipt by the RRBs and (2) the rate of heart transplantation during this travel time, stratified by whether the applications were eventually approved or denied. Additionally, we estimated how many listed patients were skipped by candidates who received transplants with exceptions that were ultimately denied.138 transplant centers submitted status exception requests on behalf of 11 508 adult candidates during the study period, of whom 913 (7.9%) received a denial at least once. The median time from obtaining status upgrades to application receipt by the RRBs was 3 days. Three thousand seven out of 11 508 (26.1%) patients received transplants before the RRBs even received their applications, with 174 (19.1%) among 913 with eventual denials and 2833 (26.7%) among 10 595 with approvals. The cumulative incidence of heart transplantation before application receipt for eventual denials was 19.1% (95% CI, 16.6%-21.7%), and that for approvals was 27.2% (95% CI, 26.4%-28.0%; P<0.001) at 2 weeks. Candidates who received transplants despite being denied exceptions bypassed more than 11 thousand potential transplant recipients.More than 25% of patients with status exception requests receive heart transplants before their applications are even received by their RRBs, raising significant concerns about the fairness of retrospective review of exception requests for the allocation of donor hearts.

    View details for DOI 10.1161/CIRCHEARTFAILURE.125.013994

    View details for PubMedID 42329622

    View details for PubMedCentralID PMC13288750

  • Artifactual Declines in Durable LVAD Utilization among Heart Transplant Candidates: Selection Bias in Transplant Registries. The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation Ahn, D. J., Lyden, G. R., Attia, A., Nakayama, T., Narang, N., Sasaki, K., Parker, W. F., Khush, K. K. 2026

    Abstract

    The Organ Procurement and Transplantation Network (OPTN) Standard Transplant Analysis and Research (STAR) files are commonly used to study use of mechanical circulatory support (MCS) among heart transplant candidates. However, the STAR MCS file reports devices only for candidates removed from the waitlist, whereas the Scientific Registry of Transplant Recipients (SRTR) MCS file includes devices for all candidates. We compared the STAR and SRTR MCS files in estimating trends in LVAD support and waitlist outcomes among heart transplant candidates with durable LVADs.We identified adult heart transplant candidates who obtained durable LVADs between October 18, 2018 and December 31, 2024 using MCS files from STAR (N=4,182) and SRTR (N=4,919). We estimated the cumulative incidence of transplantation and death/deterioration in both cohorts and analyzed LVAD prevalence at bimonthly intervals from October 2018 to April 2025.The SRTR cohort showed stable LVAD prevalence (30.7%-37.4%). In contrast, the STAR cohort constructed from the MCS file showed a 92.5% decline in LVAD prevalence (1,740 to 131 candidates), despite 971 candidates listed with status 4 for LVAD support on April 30, 2025. The STAR cohort demonstrated higher 3-year cumulative incidence of transplantation (66.7% vs 54.4%) and death/deterioration (10.1% vs 4.5%) after LVAD implantation. When we reran STAR-based analyses with both MCS and status justification files, prevalence and outcomes matched SRTR estimates.The STAR MCS file excludes LVADs among currently listed candidates, producing artifactual declines in LVAD prevalence and incidence and inflated waitlist outcomes. Awareness of registry construction is essential for accurate interpretation of LVAD-related outcomes.

    View details for DOI 10.1016/j.healun.2026.06.002

    View details for PubMedID 42263896

  • Donor Warm Ischemia Time Modifies Susceptibility to Cold Ischemia in Donation After Circulatory Death Kidney Allografts Under Hypothermic Machine Perfusion. Transplantation Nakayama, T., Attia, A., Ahn, D. J., Endo, Y., Kashyap, R. S., Hernández-Alejandro, R., Sasaki, K., Bekki, Y. 2026

    Abstract

    Donation after circulatory death (DCD) kidneys are exposed to donor warm ischemia time (dWIT) in addition to cold ischemia. Although porcine studies suggest synergy between these insults, evidence in clinical transplantation is limited.Adult DCD kidney-only transplants performed using hypothermic machine perfusion (n = 28 698) in the United Network for Organ Sharing database (January 1, 2015, to December 31, 2023) were included. We performed 1:1:1 propensity score matching across 3 cold ischemia time (CIT) categories (short, <18 h; intermediate, 18-23 h; and long, ≥24 h) on the Kidney Donor Profile Index and estimated posttransplant survival. The incidence of delayed graft function and 5-y graft survival was evaluated in the matched cohort (6885 per group) and subgroups of dWIT (≤30, 31-45, and ≥46 min).CIT categories stratified 5-y graft survival: 76.1% in short CIT, 73.9% in intermediate CIT, and 72.1% in long CIT. Compared with short CIT group, recipients in the long CIT (≥24 h) group had higher hazards of graft loss across dWIT subgroups (for dWIT ≤30 min: hazard ratio [HR], 1.11 [95% confidence interval (CI), 1.01-1.22]; for dWIT 31-45 min: HR, 1.31 [95% CI, 1.10-1.56]; and for dWIT ≥46 min: HR, 1.56 [95% CI, 1.25-1.93]). A similar interaction was observed for delayed graft function incidence.Prolonged dWIT increases DCD kidney susceptibility to CIT, and DCD kidneys with dWIT ≥46 min resulted in detrimental graft survival when CIT exceeds ≥24 h. For DCD kidney transplantation using hypothermic machine perfusion, CIT should be minimized in kidneys with prolonged dWIT.

    View details for DOI 10.1097/TP.0000000000005758

    View details for PubMedID 42204398

  • Highly Sensitized Pediatric Kidney Candidates Have Reduced Access to Kidney Transplant in the United States. American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons Nakayama, T., Ahn, D. J., Attia, A., Bozhilov, K. K., Kirchner, V. A., Sasaki, K., Busque, S., Melcher, M. L., Pham, T. A. 2026

    Abstract

    Kidney transplantation is prioritized for children in the United States, yet equity for highly sensitized pediatric candidates remains uncertain. Using Organ Procurement and Transplantation Network data, we examined kidney-only candidates aged 0-17 years listed between December 4, 2014 and December 31, 2024 who were ever activated, comparing the Kidney Allocation System (KAS; Era 1) and the 2021 circle-based revision (KAS250; Era 2). Candidates were stratified by calculated panel-reactive antibody (cPRA) at first activation (0-20%, 21-79%, 80-99%, 100%). The primary outcome was 3-year cumulative incidence of deceased-donor kidney transplant (DDKT) in competing-risk analysis. Among 7,215 activated pediatric candidates, highly sensitized candidates accepted organs from greater distances. In both eras, candidates with cPRA 80-99% (Era 1: SHR 0.46, 95%CI 0.36-0.59; Era 2: SHR 0.53, 95%CI 0.42-0.67) and cPRA 100% (Era 1: SHR 0.28, 95%CI 0.16-0.48; Era 2: SHR 0.28, 95%CI 0.18-0.43) had persistently reduced access to DDKT (all p<0.001). While non-sensitized candidates had higher DDKT rates than adults, those with cPRA 80-99% or 100% had similar rates to adults. Findings suggest that pediatric prioritization does not fully extend to highly sensitized children, supporting the need for broader sharing.

    View details for DOI 10.1016/j.ajt.2026.05.008

    View details for PubMedID 42142590

  • Current status of split liver transplantation using machine perfusion in the United States. HPB : the official journal of the International Hepato Pancreato Biliary Association Nakayama, T., Ito, R., Attia, A., Ahn, D. J., Ichida, H., Shiraki, S., Sasaki, K. 2026

    View details for DOI 10.1016/j.hpb.2026.04.465

    View details for PubMedID 42156276

  • Status Exceptions and Misalignment of Medical Urgency in U.S. Pediatric Heart Transplantation. Journal of the American College of Cardiology Ahn, D. J., Attia, A., Nakayama, T., Narang, N., Daly, K., Khush, K. K., Parker, W. F., Sasaki, K. 2026

    Abstract

    Pediatric heart transplant candidates experience high waitlist mortality, in part because of limited availability of appropriate donor hearts. Transplant physicians can request status exceptions to increase priority for candidates, but this practice may contribute to overcrowding of high-priority statuses. In 2021, the National Heart Review Board (NHRB) was established to standardize exception review, but its impact remains unknown.The goal of this study was to determine whether exceptions are granted to children at high risk of death on the waitlist and the impact of the NHRB on outcomes.Using Organ Procurement and Transplantation Network data, we identified all pediatric heart transplant candidates listed March 2016 through March 2025. We estimated the association between status exceptions and waitlist mortality using mixed-effects Cox proportional hazards models and compared concordance indices for the current system vs a hypothetical system without exceptions.Among 6,026 candidates, 745 (12.4%) died or deteriorated and 1,668 (27.7%) received exceptions. Exception recipients had a significantly lower waitlist mortality risk than standard criteria patients (HR: 0.41; 95% CI: 0.31-0.55; P < 0.001) and the NHRB's impact on this association was nonsignificant (P = 0.62). We observed significant heterogeneity in waitlist mortality within status 1A, with exception recipients having the highest survival. When modeling waitlist mortality, the concordance index improved from 0.694 (95% CI: 0.682-0.706) with exceptions to 0.713 (95% CI: 0.700-0.724) without exceptions (P < 0.001).Pediatric heart transplant candidates granted status exceptions have significantly lower medical urgency than those meeting standard criteria. Implementation of a national review board did not result in improved alignment between waitlist mortality and listing status.

    View details for DOI 10.1016/j.jacc.2026.01.052

    View details for PubMedID 41778948

  • Potential Double Counting in Meta-Analysis of Combined Heart-liver Transplantation. Transplantation Nakayama, T., Attia, A., Ahn, D. J., Sasaki, K. 2026

    View details for DOI 10.1097/TP.0000000000005642

    View details for PubMedID 41604423

  • Current status of minimally invasive liver transplantation: a narrative review ANNALS OF LAPAROSCOPIC AND ENDOSCOPIC SURGERY Nakayama, T., Attia, A., Ahn, D. J., Sasaki, K., Margonis, G. 2026; 11
  • Donor-Recipient Age Mismatch and Long-Term Graft Outcomes After Adolescent Liver Transplant. JAMA network open Nakayama, T., Jensen, A. R., Attia, A., Ahn, D. J., Firl, D. J., Kwong, A., Charu, V., Melcher, M. L., Esquivel, C. O., Sasaki, K. 2026; 9 (1): e2552779

    Abstract

    Importance: Donor-recipient age mismatch is an established risk factor in adult liver transplants (LTs), yet its effect in adolescents, who require long-term graft durability, has not been fully characterized. Despite pediatric prioritization, some adolescent donor livers are allocated to adults, limiting access to age-matched grafts for adolescents.Objective: To assess whether a donor-recipient age difference of 10 or more years is associated with inferior graft survival in LTs among adolescents and to estimate the benefits of broader geographic sharing of adolescent donor livers.Design, Setting, and Participants: This retrospective, registry-based case-control study used data from the Organ Procurement & Transplantation Network database, a nationwide US transplant registry. Participants were adolescents aged 12 to 17 years who received liver-only grafts from donation after brain death between March 1, 2002, and December 31, 2024, with follow-up until April 4, 2025. Propensity score matching (1:1) was performed on graft type and size mismatch, donor sex, donor-recipient sex mismatch, transplant center volume, and recipient variables.Exposure: Donor-recipient age difference of 10 or more years (age-mismatched graft) vs less than 10 years (age-matched graft).Main Outcomes and Measures: The primary outcome was 10-year graft survival. The secondary outcome was 10-year overall survival. Waiting time to an age-matched graft offer under alternative donor-sharing radii (1500 nautical miles [NM], 1000 NM, or no limit vs 500 NM) were also estimated.Results: Among 2020 adolescents receiving LTs (median age, 15.0 [IQR, 13.0-16.0] years; 1081 [53.5%] female), 612 (30.3%) received age-mismatched grafts (median donor age, 36.0 [IQR, 29.0-45.0] years) and 1408 (69.7%) received age-matched grafts (median donor age, 16.0 [IQR, 13.0-17.0] years). The age-mismatched group had a higher proportion of recipient candidates in the intensive care unit at transplant (287 [46.9%] vs 250 [17.8%]; P<.001). After propensity score matching (n=526 per group), 10-year graft survival was 61.5% in the age-mismatched group and 74.2% in the age-matched group (P<.001), with consistent results across recipients' pretransplant hospitalization status. A simulation estimated that expanding the adolescent allocation radius to 1000 NM would allow 90% of adolescent candidates to receive age-matched offers within 15 days, compared with 44 days under the current 500-NM limit.Conclusions and Relevance: In this case-control study of a US national cohort of adolescents receiving LT, donor-recipient age mismatch of 10 or more years was associated with inferior graft survival. Broader allocation of adolescent donors may improve access to age-matched grafts and long-term outcomes.

    View details for DOI 10.1001/jamanetworkopen.2025.52779

    View details for PubMedID 41499116

  • Renal Resistance on Hypothermic Machine Perfusion and Acceptance of Deceased Donor Kidney Allografts. Journal of the American Society of Nephrology : JASN Nakayama, T., Attia, A., Ahn, D. J., McCabe, M., Endo, Y., Kashyap, R. S., Pham, T. A., Melcher, M. L., Sasaki, K., Bekki, Y. 2025

    View details for DOI 10.1681/ASN.0000000986

    View details for PubMedID 41563235

  • Low Rates of Inotropic Support and Durable Left Ventricular Assist Device Placement among Status 2 Heart Transplant Candidates with Temporary Mechanical Circulatory Support. The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation Ahn, D. J., White, M., Ran, G., Narang, N., Kanwar, M., Parker, W. F. 2025

    Abstract

    After the 2018 heart allocation policy change, status 2 listings with temporary mechanical circulatory support (tMCS) have increased while listings with durable left ventricular assist devices (LVADs) have decreased. Treatment of cardiogenic shock varies geographically, but how often patients with status 2 are supported by inotropes prior to tMCS and receive durable LVADs is unknown.Using the Scientific Registry of Transplant Recipients, we identified all adult heart transplant candidates who received an intra-aortic balloon pump (IABP) or percutaneous endovascular ventricular assist device (PEVAD) between October 18, 2018 and December 31, 2023 and subsequently obtained status 2. We assessed the rate of overall utilization and between-center variation in use of a priori inotropic support meeting status 3 criteria and durable LVAD implantation within 6 weeks after receiving status 2.During the study period, 6,010 patients with tMCS obtained status 2 (PEVADs: n = 1,957; IABPs: n = 4,053). Transplant centers reported use of inotropes meeting status 3 criteria in 7.2% of patients prior to IABP or PEVAD placement. The cumulative incidence of durable LVAD implantation within 6 weeks after obtaining status 2 was 2.7% (95% CI [2.6%, 2.9%]). Reported rates of inotropic support prior to tMCS and durable LVAD implantation varied significantly by US transplant center (0% to 38.8%, p < 0.001 and 0% to 33.3%, p < 0.001, respectively).US heart transplant centers rarely support candidates with inotropes meeting status 3 criteria prior to initiating tMCS and do not routinely transition patients with status 2 for tMCS to durable LVAD support.

    View details for DOI 10.1016/j.healun.2025.11.002

    View details for PubMedID 41241033

  • Association of Non-Standardized MELD Score Exceptions with Waitlist Mortality in Adult Liver Transplant Candidates. American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons Ahn, D. J., Kwong, A. J., Wall, A. E., Parker, W. F. 2024

    Abstract

    In the US liver allocation system, non-standardized MELD exceptions increase the waitlist priority of candidates whose MELD scores are felt to underestimate their true medical urgency. We determined whether NSEs accurately depict pre-transplant mortality risk by performing mixed-effects Cox proportional hazards models and estimating concordance indices. We also studied the change in frequency of NSEs after the National Liver Review Board's (NLRB) implementation in May 2019. Between June 2016 and April 2022, 60,322 adult candidates were listed, of which 10,280 (17.0%) received an NSE at least once. The mean allocation MELD was 23.9, an increase of 12.0 points from the mean laboratory MELD of 11.9 (p < 0.001). A one-point increase in allocation MELD score due to an NSE was associated with, on average, a 2% reduction in hazard of pre-transplant death (cause-specific HR 0.98, 95% CI [0.96, 1.00], p = 0.02) compared to those with the same laboratory MELD. Laboratory MELD was more accurate than allocation MELD with NSEs in rank-ordering candidates (c-index 0.889 vs 0.857). The proportion of candidates with NSEs decreased significantly after the NLRB from 21.5% to 12.8% (p < 0.001). NSEs substantially increase the waitlist priority of candidates with objectively low medical urgency.

    View details for DOI 10.1016/j.ajt.2024.09.028

    View details for PubMedID 39341343

  • Cost effectiveness of commercial portable ex vivo lung perfusion at a low-volume US lung transplant center ARTIFICIAL ORGANS Kent, J., Nordgren, R., Ahn, D., Lysandrou, M., Diaz, A., Fenton, D., Wignakumar, T., McMeekin, N., Salerno, C., Donington, J., Madariaga, M. L. 2024

    Abstract

    Portable ex vivo lung perfusion during lung transplantation is a resource-intensive technology. In light of its increasing use, we evaluated the cost-effectiveness of ex vivo lung perfusion at a low-volume lung transplant center in the USA.Patients listed for lung transplantation (2015-2021) in the United Network for Organ Sharing database were included. Quality-of-life was approximated by Karnofsky Performance Status scores 1-year post-transplant. Total transplantation encounter and 1-year follow-up costs accrued by our academic center for patients listed from 2018 to 2021 were obtained. Cost-effectiveness was calculated by evaluating the number of patients attaining various Karnofsky scores relative to cost.Of the 13 930 adult patients who underwent lung transplant in the United Network for Organ Sharing database, 13 477 (96.7%) used static cold storage and 453 (3.3%) used ex vivo lung perfusion, compared to 30/58 (51.7%) and 28/58 (48.3%), respectively, at our center. Compared to static cold storage, median total costs at 1 year were higher for ex vivo lung perfusion ($918 000 vs. $516 000; p = 0.007) along with the cost of living 1 year with a Karnofsky functional status of 100 after transplant ($1 290 000 vs. $841 000). In simulated scenarios, each Karnofsky-adjusted life year gained by ex vivo lung perfusion was 1.00-1.72 times more expensive.Portable ex vivo lung perfusion is not currently cost-effective at a low-volume transplant centers in the USA, being 1.53 times more expensive per Karnofsky-adjusted life year. Improving donor lung and/or recipient biology during ex vivo lung perfusion may improve its utility for routine transplantation.

    View details for DOI 10.1111/aor.14816

    View details for Web of Science ID 001253928700001

    View details for PubMedID 38924545

  • The Accuracy of Nonstandardized MELD/PELD Score Exceptions in the Pediatric Liver Allocation System. Transplantation Ahn, D. J., Zeng, S., Pelzer, K. M., Barth, R. N., Gallo, A., Parker, W. F. 2023

    Abstract

    BACKGROUND: In the United States, over half of pediatric candidates receive exceptions and status upgrades that increase their allocation model of end-stage liver disease/pediatric end-stage liver disease (MELD/PELD) score above their laboratory MELD/PELD score. We determined whether these "nonstandardized" MELD/PELD exceptions accurately depict true pretransplant mortality risk.METHODS: Using data from the Scientific Registry of Transplant Recipients, we identified pediatric candidates (<18 y of age) with chronic liver failure added to the waitlist between June 2016 and September 2021 and estimated all-cause pretransplant mortality with mixed-effects Cox proportional hazards models that treated allocation MELD/PELD and exception status as time-dependent covariates. We also estimated concordance statistics comparing the performance of laboratory MELD/PELD with allocation MELD/PELD. We then compared the proportion of candidates with exceptions before and after the establishment of the National Liver Review Board.RESULTS: Out of 2026 pediatric candidates listed during our study period, 403 (19.9%) received an exception within a week of listing and 1182 (58.3%) received an exception before delisting. Candidates prioritized by their laboratory MELD/PELD scores had an almost 9 times greater risk of pretransplant mortality compared with candidates who received the same allocation score from an exception (hazard ratio 8.69; 95% confidence interval, 4.71-16.03; P < 0.001). The laboratory MELD/PELD score without exceptions was more accurate than the allocation MELD/PELD score with exceptions (Harrell's c-index 0.843 versus 0.763). The proportion of patients with an active exception at the time of transplant decreased significantly after the National Liver Review Board was implemented (67.4% versus 43.4%, P < 0.001).CONCLUSIONS: Nonstandardized exceptions undermine the rank ordering of pediatric candidates with chronic liver failure.

    View details for DOI 10.1097/TP.0000000000004720

    View details for PubMedID 37408100

  • Association of High-Priority Exceptions with Waitlist Mortality Among Heart Transplant Candidates. The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation Johnson, D. Y., Ahn, D., Lazenby, K., Zeng, S., Zhang, K., Narang, N., Khush, K., Parker, W. F. 2023

    Abstract

    The US heart allocation system ranks candidates using six categorical status levels. Transplant programs can request exceptions to increase a candidate's status level if they believe their candidate has the same medical urgency as candidates who meet the standard criteria for that level. We aimed to determine if exception candidates have the same medical urgency as standard candidates.Using the Scientific Registry of Transplant Recipients, we constructed a longitudinal waitlist history dataset of adult heart-only transplant candidates listed between October 18, 2018 and December 1, 2021. We estimated the association between exceptions and waitlist mortality with a mixed-effects Cox proportional hazards model that treated status and exceptions as time-dependent covariates.Out of 12,458 candidates listed during the study period, 2,273 (18.2%) received an exception at listing and 1,957 (15.7%) received an exception after listing. After controlling for status, exception candidates had approximately half the risk of waitlist mortality as standard candidates (HR 0.55, 95% CI [0.41, 0.73], p < 0.001). Exceptions were associated with a 51% lower risk of waitlist mortality among Status 1 candidates (HR 0.49, 95% CI [0.27, 0.91], p = 0.023) and a 61% lower risk among Status 2 candidates (HR 0.39, 95% CI [0.24, 0.62], p < 0.001).Under the new heart allocation policy, exception candidates had significantly lower waitlist mortality than standard candidates, including exceptions for the highest priority statuses. These results suggest that candidates with exceptions, on average, have a lower level of medical urgency than candidates who meet standard criteria.

    View details for DOI 10.1016/j.healun.2023.05.009

    View details for PubMedID 37225029

  • Assessing knowledge of end-stage kidney disease and treatment options in hospitalized African American patients undergoing hemodialysis. Chronic illness King, A., Tanumihardjo, J., Ahn, D., Zasadzinski, L., Robinson, E., Quinn, M., Peek, M., Saunders, M. 2023: 17423953231168803

    Abstract

    African Americans are more likely to develop end-stage kidney disease (ESKD) than whites and face multiple inequities regarding ESKD treatment, renal replacement therapy (RRT), and overall care. This study focused on determining gaps in participants' knowledge of their chronic kidney disease and barriers to RRT selection in an effort to identify how we can improve health care interventions and health outcomes among this population.African American participants undergoing hemodialysis were recruited from an ongoing research study of hospitalized patients at an urban Midwest academic medical center. Thirty-three patients were interviewed, and the transcribed interviews were entered into a software program. The qualitative data were coded using template analysis to analyze text and determine key themes. Medical records were used to obtain demographic and additional medical information.Three major themes emerged from the analysis: patients have limited information on ESKD causes and treatments, patients did not feel they played an active role in selecting their initial dialysis unit, and interpersonal interactions with the dialysis staff play a large role in overall unit satisfaction.Although more research is needed, this study provides information and suggestions to improve future interventions and care quality, specifically for this population.

    View details for DOI 10.1177/17423953231168803

    View details for PubMedID 37106575

  • Utility of geriatric assessments in evaluation of older adults for kidney transplantation. Clinical transplantation Campbell, K. H., Ahn, D. J., Enger, F., Zasadzinski, L., Tanumihardjo, J., Becker, Y., Josephson, M., Saunders, M. R. 2022; 36 (12): e14813

    Abstract

    While kidney transplantation has favorable outcomes in patients aged 65 years and older, many are not referred for evaluation despite having no contraindications. We wanted to determine whether incorporating geriatrics and geriatric assessments (GA), as part of kidney transplant evaluation at the University of Chicago Medicine, would help identify suitable candidates and improve transplantation outcomes among older adults.Between 2012 and 2016, as part of their multi-disciplinary transplant evaluation, 171 patients underwent an initial GA with the study geriatrician, who rated them on a five-point scale from "poor" to "excellent," and presented their cases to multidisciplinary transplant review meetings. Patients were followed until June 1st, 2021. Predictor variables included geriatric recommendation, clinical characteristics, and demographics. Outcomes of interest were mortality, receipt of transplant, and waitlist placement.Compared to patients rated "poor," "marginal," or "fair," we found that patients that the geriatrician recommended as "good" or "excellent" were more likely to be waitlisted and receive a transplant. Favorably rated patients were also less likely to be removed from the waitlist due to becoming medically unfit, meaning worsening medical morbidity, frailty, and cognitive status.Including geriatricians to perform GAs as part of the transplant evaluation process can help identify suitable elderly candidates.

    View details for DOI 10.1111/ctr.14813

    View details for PubMedID 36124434

    View details for PubMedCentralID PMC10078529

  • Advance care planning among African American patients on haemodialysis and their end-of-life care preferences. Journal of renal care Ahn, D., Williams, S., Stankus, N., Saunders, M. 2021; 47 (4): 265-278

    Abstract

    African Americans in the general population have been shown to be less likely than White ethnic groups to participate in advance care planning; however, advance care planning in the population receiving dialysis has not been well explored.We examined the prevalence of African American patients receiving haemodialysis' advance care planning discussions, and whether advance care planning impacts end-of-life care preferences.In-person interviewer-administered surveys of African American patients receiving in-centre haemodialysis.About 101 participants at three large dialysis organisation units in Chicago.Self-reported advance care planning and preferences for life-extending treatments at end-of-life.Most patients (69%) report no advance care planning discussions with their healthcare providers. Nearly all patients (92%) without prior advance care planning reported their healthcare providers approached them about advance care planning. While the majority of patients indicated preference for aggressive life-extending care, prior conversations about end-of-life care wishes either with family members or a healthcare provider significantly decreased patients' likelihood of choosing aggressive life-extending care across three scenarios (all p < 0.05). Significantly more patients reported that common end-of-life scenarios related to increased dependence/disability were "not worth living through" compared with those associated with increased burden on family, decreased cognitive function, and severe pain/discomfort.African Americans with end-stage renal disease need more frequent, culturally-sensitive advance care planning discussions. Despite a preference for aggressive life-sustaining treatments, individuals with prior advance care planning discussions were significantly less likely to support aggressive end-of-life care. End-of-life care discussions that focus on the impact of life-extending care on patients' independence could be more concordant with the values and priorities of the African American patients.

    View details for DOI 10.1111/jorc.12368

    View details for PubMedID 33616278

    View details for PubMedCentralID PMC9237830

  • Where Do I Fit In? A Perspective on Challenges Faced by Asian American Medical Students. Health equity Ahn, D. J., Garg, N., Naik, A. G., Fan, J., Wei, H., Song, B. B., Chung, K., Vela, M. B., Kim, K. E. 2021; 5 (1): 324-328

    Abstract

    Asian American medical students (AAMSs) face significant bias in the medical learning environment and are more likely than White students to perceive their school climate negatively. Little is known about the factors that contribute to AAMSs' negative experiences. This perspective aims to describe AAMSs' experiences with diversity and inclusion efforts using survey data from a midwest regional conference, Asians in Medicine: A Conference on Advocacy and Allyship. AAMS respondents reported feeling excluded from diversity and inclusion efforts and conference participants advocated for institutional culture and climate assessments stratified by race and disaggregated into Asian subgroups.

    View details for DOI 10.1089/heq.2020.0158

    View details for PubMedID 34036216

    View details for PubMedCentralID PMC8140354

  • ABHD10 is an S-depalmitoylase affecting redox homeostasis through peroxiredoxin-5. Nature chemical biology Cao, Y., Qiu, T., Kathayat, R. S., Azizi, S. A., Thorne, A. K., Ahn, D., Fukata, Y., Fukata, M., Rice, P. A., Dickinson, B. C. 2019; 15 (12): 1232-1240

    Abstract

    S-Palmitoylation is a reversible lipid post-translational modification that has been observed on mitochondrial proteins, but both the regulation and functional consequences of mitochondrial S-palmitoylation are poorly understood. Here, we show that perturbing the 'erasers' of S-palmitoylation, acyl protein thioesterases (APTs), with either pan-active inhibitors or a mitochondrial-targeted APT inhibitor, diminishes the antioxidant buffering capacity of mitochondria. Surprisingly, this effect was not mediated by the only known mitochondrial APT, but rather by a resident mitochondrial protein with no known endogenous function, ABHD10. We show that ABHD10 is a member of the APT family of regulatory proteins and identify peroxiredoxin-5 (PRDX5), a key antioxidant protein, as a target of ABHD10 S-depalmitoylase activity. We then find that ABHD10 regulates the S-palmitoylation status of the nucleophilic active site residue of PRDX5, providing a direct mechanistic connection between ABHD10-mediated S-depalmitoylation of PRDX5 and its antioxidant capacity.

    View details for DOI 10.1038/s41589-019-0399-y

    View details for PubMedID 31740833

    View details for PubMedCentralID PMC6871660

  • A Panel of Protease-Responsive RNA Polymerases Respond to Biochemical Signals by Production of Defined RNA Outputs in Live Cells. Journal of the American Chemical Society Pu, J., Chronis, I., Ahn, D., Dickinson, B. C. 2015; 137 (51): 15996-9

    Abstract

    RNA is an attractive biomolecule for biosensing and engineering applications due to its information storage capacity and ability to drive gene expression or knockdown. However, methods to link chemical signals to the production of specific RNAs are lacking. Here, we develop protease-responsive RNA polymerases (PRs) as a strategy to encode multiple specific proteolytic events in defined sequences of RNA in live mammalian cells. This work demonstrates that RNAP-based molecular recording devices can be deployed for multimodal analyses of biochemical activities or to trigger gene circuits using measured signaling events.

    View details for DOI 10.1021/jacs.5b10290

    View details for PubMedID 26652972

    View details for PubMedCentralID PMC5070793